Psychedelics
Many currently or formerly controlled substances, such as MDMA, psilocybin, cannabis, ketamine, LSD and others, have shown immense promise as therapeutic treatments for a range of mental health disorders. Here's the latest research and findings in psychedelic and next-gen medicine.
Random related stories from our 25-year archives
-
A new meta-study has concluded blood or saliva THC concentrations are not effective ways to measure cannabis-induced driving impairment. The findings indicate impairment tests should be developed instead of looking to develop a marijuana breathalyzer. -
Data from an annual drug-use survey has found use of psychedelics among US adults is at the highest point ever recorded in the survey’s history. The data also indicates alcohol and tobacco consumption is trending down but marijuana-use has increased. -
An incredible, first-of-its-kind trial testing the pain-killing properties of LSD microdoses has delivered the compelling suggestion that tiny, non-psychedelic doses of this infamous drug could serve as an effective analgesic. -
Some people find their symptoms of OCD dramatically drop after smoking cannabis, according to a new study. The improvements may only be beneficial in the short-term however, and more research is needed to understand the long-term effect of cannabis use on OCD. -
Citizen scientists have been key to the discovery of two new species of hallucinogenic fungi, joining the ranks of 140 known types of these psychoactive mushrooms. One even has longstanding roots in traditional healing medicine in mountainous Lesotho. -
New research has offered valuable insights into the long-term effects of psilocybin-assisted psychotherapy for depression. The study reports more than half the original cohort were still in remission 12 months after the acute psychedelic treatment.
Load More
Latest News
-
The US Food and Drug Administration has issued its first comprehensive guide on how psychedelic drugs should be studied in trials, signalling a shift toward recognizing the potential of these therapeutics and what's needed to see them approved. -
Does the brain really produce its own psychedelic “Spirit Molecule” to power our dream states and near-death experiences? A new study has sparked fresh debate over endogenous DMT, and its presence – or absence – in mammalian brains. -
A single psilocybin dose can significantly reduce depression in people with cancer for up to two years, according to a new study. While the study has limitations, it demonstrates the potential of psychedelic therapy in the context of cancer. -
A recent study in Denmark looked at whether a single dose of psilocybin could help people reduce their alcohol intake – and the results from the small trial are quite promising. However, they might also warrant greater scrutiny. -
A new study has uncovered a previously unknown link between the immune system and the fear response, and how psychedelics can play a role in suppressing it. The finding could improve the treatment of both mental, emotional and physical afflictions. -
A landmark clinical trial testing the effect of microdosing LSD on symptoms of ADHD recently delivered its first data readout and the results have been surprising, to say the least, raising questions over the efficacy of this popular trend. -
The cannabis-derived compound cannabidiol is gaining traction as a treatment for a multiple conditions, but it's notoriously hard for the body to use. Now a breakthrough production method has removed a major roadblock to its bioavailability. -
After comparing the long-term effects of the psychedelic psilocybin and a commonly prescribed antidepressant, new research found that both significantly reduced depression. However, psilocybin provided something more: a significant boost to quality of life. -
A poll of Americans aged 50 and over on their use of cannabis has provided some interesting insights into how often they use the drug, how and why they use it, and the behaviors they engage in while under the influence. -
We were this close to seeing Ecstasy being incorporated into therapy in the US in 2024. Now, we have to wait either a little or a lot – depending on how the chips fall. Let's have a closer look at where we're currently at. -
While CBD or cannabidiol is now widely available, widely used and generally considered safe, new research has found its use during pregnancy may produce some strange behavior in offspring and changes to the way their brains process sensory information. -
A slow-release, twice-a-week ketamine tablet significantly reduced depression symptoms, according to the results of a clinical trial. The tablet can be taken at home without medical supervision, making it more convenient than current ketamine treatments. -
Laws are opening up to support the use of medicinal psilocybin – and that requires new technology to ensure accurate, consistent dosing. Researchers have now developed a fast and reliable method of determining the potency of magic mushrooms. -
New research has found that daily users of crystal methamphetamine who turned to cannabis to manage their cravings used the stimulant drug less, especially female users. The findings suggest a new harm-reduction strategy is needed. -
A study has found that a cannabis extract can inhibit the growth of melanoma cells and trigger cell death. The next step is pre-clinical trials to investigate whether the extract can be used to treat other types of cancers.
Load More